Possible outcomes of therapeutic treatments using the spiral model.

Slides:

Advertisements

Similar presentations

Advances and Emerging Therapy for Lung Cancer

Advertisements

Statistical Issues in Incorporating and Testing Biomarkers in Phase III Clinical Trials FDA/Industry Workshop; September 29, 2006 Daniel Sargent, PhD Sumithra.

Randomized Trial of p53 Targeted Adjuvant Therapy for Patients (pts) With Organ-Confined Node-Negative Urothelial Bladder Cancer.

Clinical Perspective. Screening/Prevention Who is at risk for what type Decision to Intervene: Risk Assessment normal Evidence of Disease Disability Death.

HIGHLIGHTS IN THE MANAGEMENT OF BREAST CANCER

Metastatic Breast Cancer: One Size Does Not Fit All Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service MSKCC.

Evaluating the Effectiveness of the CTRC: Designing Quantitative and Qualitative Measures to Assess in Real Time the Value of the Center Mike Conlon, University.

Cabozantinib (XL184) in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Results from a Phase II Randomized Discontinuation Trial Hussain M et.

Chapter 6 Cancer. Frequency and Significance Cancer is the 2 nd leading cause of death in the United States Obviously, the term cancer covers many types.

종양혈액내과 R4 고원진 / pf. 김시영 Rectal cancer : state of the art in 2012 Curr Opin Oncol 2012, 24:441–447.

Stephen Joseph Galli, MD Journal of Allergy and Clinical Immunology

As is shown, men treated by radical prostatectomy had a better adjusted survival rate than men without prostate cancer suggesting selection biases for.

Antibody Drug Conjugates Services Antibody-drug conjugates Antibody-drug conjugates (ADCs) are a very important class of highly potent drugs designed as.

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth

Chemotherapy and Cancer Stem Cells

Dose-escalation patient response.

Steps to Optimizing Outcomes in Patients With Advanced Prostate Cancer

EBV DNA: a Hodgkin lymphoma biomarker?

Administration.

CD25 expression is associated with unfavorable clinical outcome.

Program Goals. The Clinical Impact of Second-Generation Antihormonal Therapy in the Treatment of mCRPC.

25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.

Figure 1 Differences in bladder cancer between genders

Representative 3-generation pedigrees for serous cancer probands suggestive of inherited cancer susceptibility. Representative 3-generation pedigrees for.

Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.

Jean-Charles Nault, Peter R. Galle, Jens U. Marquardt

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

nab-Paclitaxel targets the tumor epithelial cells.

Targeting the Androgen Pathway: Current Best Practice and Future Directions.

Proposed spiral model for prostate cancer progression.

Target disease and target populations for 21st century vaccine developmentIncluded in the list are the agents of infectious diseases for which vaccines.

Targeting Immunity in End-Stage Renal Disease

Androgen receptor alterations and outcome.

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

Metabolic Alterations as a Signpost to Early Pancreatic Cancer

Evaluating the Totality of Evidence

Clinical response to anti-ERBB3 mAb therapy in a patient with an advanced NRG1-rearranged non–small cell lung cancer. Clinical response to anti-ERBB3 mAb.

Schematic representation of the therapeutic strategies that can be applied to target ARF876L. Schematic representation of the therapeutic strategies that.

Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.

Development of 28 public molecular laboratories in France for molecular testing. Development of 28 public molecular laboratories in France for molecular.

VEGF expression in neoplastic and normal prostate tissue.

A schematic representation of NOTCH signaling through DAB1–ABL–TRIO–RHO that stimulates colorectal cancer invasion and metastasis. A schematic representation.

Molecular signatures are independent of tumor stage and grade.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.

Immunophenotypic analysis of TILs in B16 and K1735 melanoma following combination therapy with antibodies targeting PS and PD-1. Immunophenotypic analysis.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Location of the ER mutations and frequencies per cohort.

The efficacy of telomerase inhibition–based therapies, such as imetelstat, depends on the tumor telomere length at the beginning of treatment. The efficacy.

Efficacy summary for patients with gastric/GEJ adenocarcinoma (part B)

Change in FES uptake in the tumor during fulvestrant treatment.

Frequent coamplification of RTKs in MET-amplified EGC

Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)

Top, NEPC biology is estimated to drive approximately 25% of the lethal prostate cancers indicated by the blue zone. Top, NEPC biology is estimated to.

Putative molecular pathways showing how GSK3β regulates the fate of tumor cells (survival, proliferation, or apoptosis) and influences their sensitivity.

Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Combination of R848 and anti-CD200R affects activation of tumor-infiltrating.

P53-expressing tumor cells circumvent mitosis, express markers consistent with a G1-like state, and become senescent in response to continuous chemotherapeutic.

DHT-dependent phase of prostate cancer.

Serial CT scan images from patient with a partial response.

Survival, subsequent therapies, and response.

Response to crizotinib in an 8-year-old boy with refractory IMT harboring a TFG–ROS1 fusion. Response to crizotinib in an 8-year-old boy with refractory.

Blockade of cell cycle at G2-M phase in Bel-7402 cells treated with IG-105. Blockade of cell cycle at G2-M phase in Bel-7402 cells treated with IG-105.

One potential implementation for the use of outlier kinase profiling and targeting for clinical management of pancreatic cancer in a precision medicine.

Preclinical trials in mouse models of APL

Venn diagram showing the overlap of PD-L1 overexpression, MSI-NGS–high, and TML-high in all gastrointestinal tumors, with all three markers tested (N =

CD36 expression in tissue adjacent and distal to the tumor.

Curative effect of W+T treatment in vivo.

BIM expression predicts the response of patients with EGFR-mutant lung cancers. BIM expression predicts the response of patients with EGFR-mutant lung.

Immunological effects of anticancer therapy.

624. Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer: Preliminary Results Molecular.

Presentation transcript:

Possible outcomes of therapeutic treatments using the spiral model. Possible outcomes of therapeutic treatments using the spiral model. A turn in the spiral is defined through the expression or alteration of a predictive marker. Three possible outcomes of therapeutic treatment may occur based on a predictive marker that defines a turn in the spiral. Abiraterone is used as an example. After application of abiraterone, no further “turns” in the spiral occur, suggesting that the therapy may be curative (A). B, the turn may be elongated, suggesting that abiraterone is effective in reducing androgen generated from Cyp17. Following the treatment, tumor adaptation may occur, leading to the next turn in the spiral. Successful application of the correct therapeutic agent at this stage of the spiral will elongate the next turn. C, application of targeted therapy does not have a positive therapeutic effect. This result would suggest that the tumor is in a more complex phase of the disease. Christopher J. Logothetis et al. Cancer Discovery 2013;3:849-861 ©2013 by American Association for Cancer Research